Our Mission:

Pathway Therapeutics is discovering and developing best in class selective inhibitors of PI3-kinase (PI3K) and mTOR for the treatment of cancer and inflammatory diseases in targeted patient populations that are most likely to benefit.

The Next Generation of PI3-Kinase and mTOR inhibitors